Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 2, February, p. 291–297

doi: 10.17219/acem/68826

Publication type: review article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

The importance of antiangiogenic effect in multiple myeloma treatment

Agnieszka Barchnicka1,B,C,D,E,F, Małgorzata Olejniczak-Nowakowska2,E,F, Karolina Krupa-Kotara2,E,F, Sebastian Grosicki2,C,E,F

1 Department of Doctoral Studies, School of Public Health in Bytom, Medical University of Silesia in Katowice, Poland

2 Department of Cancer Prevention, School of Public Health in Bytom, Medical University of Silesia in Katowice, Poland

Abstract

Angiogenesis plays a significant role in oncogenesis, and thus it has become an attractive target for cancer treatment. It is the formation of new blood vessels that occurs physiologically as well as under pathological conditions, and may influence cancer proliferation and survival. The current therapeutic approach in oncology includes conventional chemotherapy in combination with biologically-based treatment in various perspectives, targeting not only the malignant cells, but also its microenvironment. Target treatment might be less toxic than conventional chemotherapy. In multiple myeloma, there is a close connection between bone marrow stroma, myeloma cell growth and their ability to survive. It has been reported in many clinical observations that the more advanced the multiple myeloma, the more increased the angiogenesis, and this might correlate with the treatment response. There are several angiogenesis inhibitors already registered or in clinical trials in cancer treatment. Despite the continuous research on the development of prognostic factors and introduction of new agents in the treatment, multiple myeloma still remains an incurable and debilitating disease. Some antiangiogenic agents have already been introduced in multiple myeloma treatment, but there is still a need to search for new antiangiogenic drugs and the exploitation of angiogenesis in a clinical approach.

Key words

multiple myeloma, angiogenesis, treatment, angiogenesis inhibitors

References (48)

  1. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9: 653–660.
  2. Rajkumar SV. Myeloma today: Disease definitions and treatment advances. Am J Hematol. 2016;91(1): 90–100.
  3. Rajkumar S, Kumar S. Multiple myeloma: Diagnosis and treatment. Mayo Clin Proc. 2016;91(1):101–119.
  4. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333(26):1757–1763.
  5. Otjacques E. Biological aspects of angiogenesis in multiple myeloma. Int J Hematol. 2011;94:505–518.
  6. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91(10): 3527–3561.
  7. De Bock K, Georgiadou M, Carmeliet P. Role of endothelial cell metabolism in vessel sprouting. Cell Metab. 2013;18(5):634–647.
  8. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401–410.
  9. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93:3064–3073.
  10. Rajkumar VS, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res. 2002; 8(7):2210–2216.
  11. Sezer O, Niemöller K, Eucker J, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol. 2000;79(10):574–577.
  12. Sezer O, Niemöller K, Jakob C, et al. Relationship between bone marrow angiogenesis and plasma cell infiltration and serum beta2-microglobulin levels in patients with multiple myeloma. Ann Hematol. 2001;80(10):598–601.
  13. Lee N, Lee H, Moon SY, et al. Adverse prognostic impact of bone marrow microvessel density in multiple myeloma. Ann Lab Med. 2015; 35(6):563–569.
  14. Sezer O, Jakob C, Eucker J, et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol. 2001;66:83–88.
  15. Kokonozaki M, Tsirakis G, Devetzoglou M, et al. Potential role of FLT-3 ligand in the angiogenic process of multiple myeloma. Leuk Res 2015;39:1467–1472.
  16. Mileshkin L, Honemann D, Gambell P, et al. Patients with multiple myeloma treated with thalidomide: Evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome. Haematologica. 2007; 92(8):1075–1082.
  17. Cibeira MT, Rozman M, Segarra M, et al. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. Cytokine. 2008;41(3):244–253.
  18. Grosicki S, Grosicka A, Hołowiecki J. Kliniczne znaczenie angiogenezy i czynników ją modyfikujących w onkohematologii. Wiad Lek. 2007;60(1/2):39–46.
  19. Cook K, Figg W. Angiogenesis inhibitors: Current strategies and future prospects. CA Cancer J Clin. 2010;60(4):222–243.
  20. Pour L, Svachova H, Adam Z, et al. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann Hematol. 2010;89:385.
  21. D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082–4085.
  22. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–1571.
  23. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24(3):431–436.
  24. Dmoszyńska A. Angiogeneza i leczenie antyangiogenne w szpi-czaku plazmocytowym. Onkol Prak Klin. 2009;5 (Suppl A):A56–A61.
  25. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia. 2001;15:1950–1961.
  26. Rosiñol L, Cibeira MT, Blade J, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica. 2004;89:832–836.
  27. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–2132.
  28. Guirguis AA, Ebert BL. Lenalidomide: Deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond. Curr Opin Cell Biol. 2015;37:61–67.
  29. Lu L, Payvandi F, Wu L, et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res. 2009;77:78–86.
  30. Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer. 2002;87(10):1166–1172.
  31. Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. 2005;69(1–2):56–63.
  32. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009;27(30):5008–5014.
  33. Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02. Blood. 2013;121(11):1968–1975.
  34. Chanan-Khan AA, Swaika A, Paulus A, et al. Pomalidomide: The new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J. 2013;3(9):e143.
  35. Grosicki S, Barchnicka A, Jurczyszyn A, Grosicka A. Bortezomib for the treatment of multiple myeloma. Expert Rev Hematol. 2014;7(2):173–185.
  36. Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res. 2001;7:1419–1428.
  37. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat. 2008;11(4–5):164–179.
  38. Roccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 2006;66(1):184–191.
  39. Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110:3281–3290.
  40. White D, Kassim A, Bhaskar B, Yi J, Wamstad K, Paton VE. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer. 2013;119(2):339–347.
  41. Zangari M, Anaissie E, Stopeck A, et al. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res. 2004;10(1 Pt 1):88–95.
  42. Kovacs MJ, Reece DE, Marcellus D, et al. A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase) in patients with relapsed multiple myeloma – NCIC CTG IND.145. Invest New Drugs. 2006;24:529–535.
  43. Prince HM, Honemann D, Spencer A, et al. Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: A phase 2 study of pazopanib (GW786034). Blood. 2009;113:4819–4820.
  44. Calin GA, Croce CM. MicroRNA-cancer connection: The beginning of a new tale. Cancer Res. 2006;66:7390–7394.
  45. Roccaro AM, Sacco A, Thompson B, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009;113:6669–6680.
  46. Sun CY, She XM, Qin Y, et al. Carcinogenesis. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. 2013;34(2):426–423.
  47. Gu S, Chan WY. Flexible and versatile as a chameleon: Sophisticated functions of microRNA-199a. Int J Mol Sci. 2012;13(7):8449–8466.
  48. Raimondi L, Amodio N, Di Martino MT, et al. Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity. Oncotarget. 2014;5(10):3039–3054.
© Wroclaw Medical University